85128-75-2
Chemical Structure
(22R)-Budesonide-d8
Synonym(s): (22R)-BUD-d8
- CAS No.: 85128-75-2
- Formula:C25H26D8O6
- Molecular Weight:438.58
InChIKey: VOVIALXJUBGFJZ-RYOILPRBSA-N
SMILES: OCC([C@]12[C@@]3([C@@]([C@@]4([H])[C@]([C@@]5(C(CC4)=CC(C=C5)=O)C)([H])[C@H](C3)O)([H])C[C@@]1([H])O[C@@](O2)([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])C)=O
Biological Activity: (22R)-Budesonide-d8 ((22R)-BUD-d8) is the deuterium labeled (22R)-Budesonide. (22R)-Budesonide ((22R)-BUD) is the (22R)-enantiomer of Budesonide (HY-13580). (22R)-Budesonide is a non-halogenated glucocorticoid with high local anti-inflammatory activity[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(22R)-Budesonide-d8 | (22R)-Budesonide-d8 ((22R)-BUD-d8) is the deuterium labeled (22R)-Budesonide. (22R)-Budesonide ((22R)-BUD) is the (22R)-enantiomer of Budesonide (HY-13580). (22R)-Budesonide is a non-halogenated glucocorticoid with high local anti-inflammatory activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(22R)-Budesonide-d6 | (22R)-Budesonide-d6 (Dexbudesonide-d6) is deuterium labeled (22R)-Budesonide. (22R)-Budesonide ((22R)-BUD) is the (22R)-enantiomer of Budesonide (HY-13580). (22R)-Budesonide is a non-halogenated glucocorticoid with high local anti-inflammatory activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(22R)-Budesonide | (22R)-Budesonide ((22R)-BUD) is the (22R)-enantiomer of Budesonide (HY-13580). (22R)-Budesonide is a non-halogenated glucocorticoid with high local anti-inflammatory activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Youming Lu, et al. Simultaneous quantification of 22R and 22S epimers of budesonide in human plasma by ultra-high-performance liquid chromatography-tandem mass spectrometry: application in a stereoselective pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Mar 15:921-922:27-34. [Content Brief]